Dear Colleagues,

I hope each of you is slowly beginning to feel the atmosphere of the upcoming holiday season. It's time for a well-deserved rest for all of us. As we approach the end of the year, it’s also the perfect time to reflect on our achievements and think about how we can continue to grow as an organization. One important part of this process is reviewing the results of the Employee Opinion Survey conducted in October across the entire Humaneva Group.

Thank you to everyone who participated in the survey and shared your valuable feedback. Your insights help us understand what we’re doing well and where we can improve to make our workplace even better for everyone.

This year, our overall engagement index increased to 49%, marking a 2-percentage-point improvement from last year! We also saw an increase in the percentage of highly engaged employees and a significant decrease in disengagement levels. These results reflect the positive changes we’ve made together to create a more inclusive and supportive work environment.

Our workplace continues to be perceived more positively across all areas, reflecting the strides we’ve made in fostering an inclusive and supportive environment. These results highlight the impact of our shared efforts and the value of the culture we’ve built together. While we’re proud of the progress we’ve achieved as a team, we recognize that there is still room for improvement. For instance, engagement levels can still grow, and addressing disengagement remains a priority. Building a workplace where everyone feels valued, supported, and engaged is an ongoing effort that involves all of us.

In the coming weeks, your managers will share more detailed survey results with you and your teams and facilitate discussions about the findings. This will be an opportunity for open dialogue, where your opinions and ideas will play a key role in shaping the next steps. Together, we can continue to make our company a place we’re all proud to be a part of.

Thank you once again for your contributions, feedback, and dedication throughout the year. Let’s keep working together to create a safe, innovative, and rewarding workplace for everyone.

Starting December 1st, the method of logging into NEUCAnet will change.

Below is the information about the planned changes:

Web address

The web address will remain the same: https://neucanet.neuca.pl

The login site

Below, you can find screenshots of the updated login page to guide you through the process:

Password

Password will not change. The password you are currently using will continue to work after December 1st.

Current login format: neuca/username (example: neuca/jdoe)

New login format (effective December 1st):

username@company.com

Examples:

jdoe@humaneva.com

jdoe@kapadi.com

jdoe@agaticlinical.com

jdoe@pratia.com

jdoe@hyggio.com

jdoe@neuca.com

For employees with a business email address:

After November 27th, you will receive an automatic email with information about your new login.

For employees without a business email address:

After November 27th, your manager will receive a list with your login details.

Need help?

If you encounter any difficulties logging in after December 1st, please reach out to your local HR representative or contact the IT Support / Service Desk.

This initiative is designed to support oncology Patients and their loved ones in finding Clinical Trials. Through the OncoInformer, Patients not only receive assistance in locating innovative therapies but also compassionate support from our dedicated Team of specialists.

Why did we create the OncoInformer?

Many Patients are unsure where to look for available therapies or find it difficult to navigate complex medical terminology and search tools. We aim to provide them with easier access to cutting-edge treatments. We've noticed that many Patients need guidance when exploring the world of Clinical Trials, and the OncoInformer was created to fulfill that need.

How does the service work?

Through the OncoInformer, our team helps locate potential Clinical Trials both within Pratia Sites and other institutions. Patients and their families can reach us by completing a contact form on our website at pratia.pl/onkoinformator. After submitting the form, our Call Center contacts Patient within 72 hours. Additionally, Patients can directly call our helpline, available Monday to Friday from 8 AM to 8 PM. Please note that the OncoInformer service is available only in Poland and is entirely free of charge.

Our mission is to make it easier for Patients in Poland to access the latest therapies available through Clinical Trials. We are here to support them and their families every step of the way in finding the right Clinical Trial. To date, over 100 Patients have already benefited from the OncoInformer.

Kapadi at ESMO 2024: A Powerful Presence in Oncology's Global Stage The European Society for Medical Oncology (ESMO) Congress is the premier event in the oncology world. In this vibrant hub, groundbreaking research, innovative therapies, and the brightest minds in the field converge. This year's congress, held in Barcelona from September 13-17, saw Kapadi make its first appearance at a European conference, showcasing its commitment to advancing cancer care globally. Our team's participation wasn't just attendance; it was an active contribution to the ongoing conversation shaping the future of oncology.

Our dedicated team, consisting of Krystyna Kowalcyk, Bill Leone, Birgit Mund, Andrew Bradshaw, Marga Galan, and Patricia Perez, used the conference for extended networking activities, as ESMO provides an unparalleled opportunity for collaboration. Our team had the chance to meet with existing and potentially new clients, fellow researchers, sites and investigators, and service providers in the oncology space.

In addition to the networking activities, Kapadi made a splash at ESMO 2024! Our exhibition booth was a buzzing hub of activity, introducing our brand to a wider European audience and solidifying our presence in the market. We connected with clients, forging new relationships and strengthening existing ones. The energy was electric, and the response to our innovative solutions was overwhelmingly positive. ESMO 2024 was a resounding success, propelling Kapadi to new heights of brand awareness and paving the way for exciting future growth across Europe.

Kapadi's active participation in ESMO 2024 reinforced our commitment to pushing the boundaries of cancer research. The knowledge gained, the collaborations forged, and the research shared will undoubtedly contribute to our ongoing efforts to develop innovative solutions and improve the lives of cancer patients globally. We look forward to continuing this momentum, building upon the successes of ESMO 2024 to drive further advancements in the fight against cancer.

We are excited to announce that Chloe Rose, Dominique Smith, Krzysztof Emanuel, Nicole Lehmpfuhl and Ute Bertelsmann will be attending Europe’s largest and most senior vaccine event, the World Vaccine Congress, from 28th-31st October in Barcelona!💉

As part of our advertisement opportunity with the conference organizers, we have secured Pratia's presence in a way that every attendee will come across our brand. As a touchpoint, the minute they walk in the building our branded canvas bags will be handed out by the entrance, each containing a Pratia leaflet. Other marketing materials prepared by us (social media content for the company's page but also for our employee's pages, vCards and SQRs) aim to raise awareness of our experts' participation in this esteemed congress and to encourage potential contacts to connect and schedule a meeting with them while in Barcelona.

"With our strong position in the clinical research industry, we invite you to join us for insightful discussions and explore opportunities for collaboration. Don’t miss this chance to connect with Pratia’s experts and discover how we’re advancing clinical trials for cutting-edge vaccine development."

As we approach the 10-year mark since we began our journey in clinical trials alongside the Neuca Group, I find myself reflecting on how far we've come. Many of us started this journey together as the first employees, beginning with just a small segment of what has now become one of the largest integrated clinical research platforms in Europe and one of the few of its kind in the world. With the tremendous support of both the NEUCA and Humaneva Group Teams, we have built an organization that has a real, tangible impact on human lives.

But as you all know, the research and life science industry is tough, never sleeps, and constantly evolves. If we want to continue our mission of improving patients' lives through clinical research, we must keep moving forward. We need to expand our platform to reach every patient in the world. The market is aggressive, and we can't achieve this alone—not even with the support of our wonderful parent company, Neuca Group. This is why we have decided to bring in a strategic partner, a minority investor, to support our endeavors.

I am thrilled to announce that Humaneva Inc., our holding company registered in Delaware, which includes Kapadi, Pratia, Hyggio, and their related subsidiaries, along with the NEUCA Board of Directors, has successfully closed a deal with Viking Global Investors, one of the largest hedge funds in the world. Viking, managing over $50 billion in assets, has acquired a minority stake in Humaneva Inc. for $50 million. Furthermore, Viking has been granted a one-year option to invest an additional $50 million in Humaneva Inc., reinforcing our growth strategy and commitment to innovation.

This partnership is not just about money; it's about fulfilling our dreams and meeting our patients' needs and hopes. This is how we can make a true global impact on people's lives and our future generations.

I would like to express my deepest gratitude to all of you. Each of you has played a crucial role in keeping this organization in the best shape ever, and this investment is clear evidence that you have done an outstanding job. Many of you have been with us almost since the beginning, and the same goes for our colleagues from the companies we have acquired over time. You are the ones who have made the difference and transformed our organization to reach this milestone.

I also want to extend my heartfelt thanks to the Neuca Shareholders, Board, and Central Teams who have supported this strategic and exceptional move within the group. They have taken significant risks, allowing us to grow and expand over the last 10 years in the very volatile life sciences industry. Without their support over the past decade, we would never have been able to achieve this milestone.

Looking ahead, nothing will change in our core mission. We will continue doing what we do best—bringing clinical research as a care option to our patients and supporting our sponsors in this endeavor. Humaneva will scale up and grow its operations in the countries where we are already present, maintaining our #1 position in each of them. We will also expand into new continents and countries, with a particular focus on the US and the APAC region for investments and M&A growth.

Thank you for your unwavering support and for being a part of this journey. Together, we will continue to make a profound impact on people's lives.

Tomek Dąbrowski, CEO HUMANEVA Inc.

Karolina Grzelska: What are the methods for finding patients for clinical trials?

Marek Kotlarski: There are many ways. If a patient actively engages in seeking information, it’s always a very good sign. In oncology, it's important to have a Plan B – even if the current treatment is effective, it’s always good to have an alternative, because no one can guarantee a complete cure. Even in cases of cancers with good prognoses, there are always some uncertainties regarding the course of treatment.

Returning to the topic of finding patients, it happens that people contact us themselves because they heard about this option from their loved ones, from advertisements, or from doctors. The paths are varied, but people often actively seek help. Sometimes they come just to talk and find out if their loved one could be included in a trial.

There are also patients who follow traditional treatment paths, which can also yield great results. In clinical trials, we offer treatments that won’t be available on the market for several years, but which can already be effective. Our patients have the opportunity to benefit from these therapies earlier, and it’s worth noting that these are substances that have been thoroughly evaluated for toxicity and safety in earlier stages of clinical trials.

Of course, every clinical trial carries some risk, just like any medications that have already been approved for use. Sometimes we’re unable to prove the superiority of a new drug over standard treatment. However, the drugs that enter clinical trials have already been carefully evaluated and tested to ensure patient safety. Contrary to common fears, it’s not like we are blindly administering drugs and hoping they work.

The first group of patients is those who find us themselves, not the other way around. We, on the other hand, look for patients through various efforts, both organized by us and through patient support groups. Online forums and support groups are also places where people seek information and help regarding specific diseases. However, the method of searching can vary.

Another source of patients is doctors working within the public healthcare system (NFZ), who treat patients and see the need to offer them something more. When standard treatment options are exhausted, they look for alternatives. Sometimes doctors notice that the clinical trial we’re currently conducting offers the patient a better chance at a given stage of treatment.

It’s important to note that clinical trials have very specific criteria for patient inclusion. Often, trial sponsors are looking for a very specific population. So, we can’t always and not everyone can be “matched” to the current trials. However, we always strive to open new studies to accommodate as many cases as possible.

Doctors working in outpatient clinics and hospital wards can propose clinical trial participation if they see that it could benefit the patient.

Sometimes, the paths that lead patients to trials are as complicated as life itself. The healthcare system, although challenging to navigate, functions a bit differently in oncology thanks to the presence of coordinators who help patients.

We search for patients both within our centers and sometimes at “competitors'” centers. Our advantage over the public healthcare system (NFZ) is that we can dedicate more time to the patient, which is very important to us as doctors. Unfortunately, in the NFZ system, there’s often no time for long conversations with patients or for a thorough analysis of treatment options. The system is constantly in crisis.

KG: What are the biggest concerns of patients?

MK: The main concern patients have is that they don’t want to be treated like "guinea pigs." There’s a perception that clinical trials are experiments on them. In their minds, these are experiments reminiscent of times long gone. However, the fundamental element of clinical trials is always to ensure patient safety.

We cannot open a study that would worsen a patient’s prognosis compared to existing treatments. Every trial must go through an ethics committee. A patient also has the right to withdraw from the trial at any time and return to their previous treatment regimen. This ensures that the patient is not forced into anything. The informed consent form is the patient's document, which they can consult with another doctor if they wish.

KG: What could interfere with a trial?

MK: If a patient agrees to participate in a trial, their only obligation is to follow the trial protocol, for example, taking the prescribed medication daily. Of course, there are situations where a patient forgets to take their medication, but that’s usually not an issue.

The patient must attend scheduled appointments, though we try to be flexible to accommodate their needs. Some requirements, however, come from the trial protocol and must be followed. For example, in early-phase trials, regular blood draws are necessary, which may be burdensome for the patient.

Sometimes patients withdraw due to the number of medications they would need to take. In oncology, patients are generally more motivated, but there are exceptions. Most patients who start treatment continue without major issues, though there are occasional instances where a patient forgets to take their medication.

We have many trials that are showing promising results. However, the recruitment process is limited by time and the number of participants, so sometimes after a few months, we have to close recruitment, but new trials open soon after.

Patients who come to us are generally more aware of their disease and treatment options. They are able to assess the benefits of participating in clinical trials and are eager to take part. Thanks to their high motivation, we can establish good cooperation with them and conduct treatment effectively.

KG: Thank you for your time!

LEARN ABOUT ITS PROVISIONS

We are implementing the policy throughout the NEUCA Group, including in the HUMANEVA Group's clinical trials segment for Pratia, Hyggio and Kapadi. In doing so, we are bringing our organization in line with the standards for reporting sustainability (ESG) issues.

We are obligated to do so by European Union law. The standards are mandatory for the NEUCA Group. The policy collects in a single document our commitments to respecting and upholding the human rights of employees, co-workers and contractors.

Below are some of them:

❌ We do not accept or condone any form of forced labor or child labor,

✅ We create safe working conditions,

✅ We fight corruption and bribery,

The rules contained in the Policy are not new. They are based on our organization's applicable regulations, values and commitments enshrined in, among others,

☑️ Group Code of Conduct,

☑️ Responsible Business Strategy,

☑️ Anti-Corruption Code,

☑️ Set of Rules of Conduct for Suppliers and Subcontractors of the NEUCA Group.

The policy sets a global standard for human rights conduct throughout our organization. Familiarize yourself with its contents.